Home > Healthcare > Medical Devices > Surgical Devices > Neurothrombectomy Devices Market

Neurothrombectomy Devices Market Share

Report ID: GMI7700
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Neurothrombectomy Devices Market Share

The neurothrombectomy devices industry is consolidated, with key players including Medtronic Plc, Stryker Corporation, Penumbra, Inc., MicroVention, Inc. (Terumo Corporation) and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in February 2023, Penumbra, Inc. launched the lightning flash mechanical thrombectomy system following FDA clearance. This innovative system integrates Penumbra's Lightning intelligent aspiration technology, enhanced with dual clot detection algorithms. The Lightning Flash device is specifically designed for the swift removal of substantial blood clots, encompassing venous thrombus and pulmonary emboli. This approval expands the company's product portfolio, positioning it with a competitive edge in the market.

Neurothrombectomy Devices Market Companies

Some of the eminent market participants operating in the neurothrombectomy devices industry include:

Medtronic Plc
Stryker Corporation
Penumbra, Inc.
Johnson & Johnson
MicroVention, Inc. (Terumo Corporation)
Acandis GmbH
Phenox Inc.(Wallaby Medical)
Vesalio, LLC
AngioDynamics, Inc.
Abbott Laboratories
Edward Lifesciences Corporation
Boston Scientific Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of neurorehabilitation devices was worth USD 1.9 billion in 2023 and is estimated to reach USD 5.8 billion by 2032, as they are designed to aid in the rehabilitation and recovery of individuals with neurological disorders or injuries.

The neurorobotics segment of neurorehabilitation devices industry garnered USD 604 million in 2023 and will grow significantly through 2032, as these devices enable intensive and repetitive training, promoting neuroplasticity and functional recovery.

The U.S. neurorehabilitation devices market accounted for USD 693 million in 2023 and is predicted to witness substantial growth through 2032, attributed to the country's advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of neurological disorders.

Bioventus LLC, Ectron Ltd., Hocoma (DIH Medical), BIOMETRICS LTD., Bionik Laboratories Corp., BioXtreme Ltd., Ekso bionics holdings, Inc., Kinestica, Saebo, Inc., Abbott Laboratories, Emotiv Inc., BrainCo, Inc, Permobil AB, and Medtronic Plc.